Literature DB >> 27423200

Direct Bypass Versus Indirect Bypass in Adult Moyamoya Angiopathy with Symptoms or Hemodynamic Instability: A Meta-analysis of Comparative Studies.

Hoon Kim1, Dong-Kyu Jang2, Young-Min Han3, Jae Hoon Sung4, Ik Seong Park1, Kwan-Sung Lee5, Ji-Ho Yang6, Pil Woo Huh7, Young Sup Park3, Dal-Soo Kim8, Kyung-Do Han9.   

Abstract

BACKGROUND: It remains controversial which bypass methods are optimal for treating adult moyamoya angiopathy patients. This study aimed to analyze the literature about whether different bypass methods affect differently outcome results of adult moyamoya patients with symptoms or hemodynamic instability.
METHODS: A systematic search of the PubMed, Embase, and Cochrane Central databases was performed for articles published between 1990 and 2015. Comparative studies about the effect of direct or combined bypass (direct bypass group) and indirect bypass (indirect bypass group) in patients with moyamoya angiopathy at 18 years of age or older were selected. For stroke incidence at the end of the follow-up period, the degree of angiographic revascularization, hemodynamic improvement, and perioperative complication rates within 30 days, pooled relative risks were calculated between the 2 groups with a 95% confidence interval.
RESULTS: A total of 8 articles (including 536 patients and 732 treated hemispheres) were included in the meta-analysis. There were no significant differences between the 2 groups when we compared the overall stroke rate, the hemodynamic improvement rate, or the perioperative complication rate at the end of the follow-up period. The direct bypass group, however, had a lower risk than the indirect bypass group for obtaining a poor angiographic revascularization rate (risk ratio, 0.35; 95% confidence interval, 0.15-0.84; P = 0.02).
CONCLUSIONS: The current meta-analysis suggests that the direct or combined bypass surgical method is better for angiographic revascularization in adult moyamoya patients with symptoms or hemodynamic instability. Future studies may be necessary to confirm these findings.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adult; Bypass; Direct; Indirect; Meta-analysis; Moyamoya

Mesh:

Year:  2016        PMID: 27423200     DOI: 10.1016/j.wneu.2016.07.009

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

Review 1.  Surgical Treatment of Adult Moyamoya Disease.

Authors:  Si Un Lee; Chang Wan Oh; O-Ki Kwon; Jae Seung Bang; Seung Pil Ban; Hyoung Soo Byoun; Tackeun Kim
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

2.  Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures.

Authors:  Markus Kraemer; Rusen Karakaya; Toshinori Matsushige; Jonas Graf; Philipp Albrecht; Hans-Peter Hartung; Peter Berlit; Rudolf Laumer; Frank Diesner
Journal:  J Neurol       Date:  2018-08-28       Impact factor: 4.849

3.  Side-to-side reverse superficial temporal artery to M4 middle cerebral artery bypass for common carotid artery occlusion with bonnet collaterals: illustrative case.

Authors:  Lekhaj C Daggubati; Varun Padmanaban; Ephraim W Church
Journal:  J Neurosurg Case Lessons       Date:  2021-05-10

4.  Risk factors for postoperative ischemic complications in pediatric moyamoya disease.

Authors:  Xiaofeng Deng; Peicong Ge; Rong Wang; Dong Zhang; Jizong Zhao; Yan Zhang
Journal:  BMC Neurol       Date:  2021-06-22       Impact factor: 2.474

5.  Surgical Management of Failed Revascularization in Moyamoya Vasculopathy.

Authors:  Kristin Lucia; Güliz Acker; Nicolas Schlinkmann; Stefan Georgiev; Peter Vajkoczy
Journal:  Front Neurol       Date:  2021-06-29       Impact factor: 4.003

6.  Quantitative Angiographic Hemodynamic Evaluation After Revascularization Surgery for Moyamoya Disease.

Authors:  Yu Chen; Li Ma; Shuo Yang; Jan-Karl Burkhardt; Junlin Lu; Xun Ye; Weijian Jiang; Zeguang Ren; Rong Wang; Xiaolin Chen; Yuanli Zhao
Journal:  Transl Stroke Res       Date:  2020-02-13       Impact factor: 6.800

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.